Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Steps Up Try To Regain Leading Role In iPS Research

This article was originally published in PharmAsia News

Executive Summary

Japan is making an additional effort to regain its standing as a leader in the study of induced pluripotent stem cells by tying in with foreign institutions. Kyoto University is discussing a possible alliance with Harvard University of the United States for joint iPS study. The school also expects to begin a joint study of diabetic treatment soon with Novocell, a U.S. biotech. The new alliances come on top of a Kyoto U. link with the University of Toronto in Canada last year. Japan has felt a sense of urgency to step up its iPS research after losing the lead in the field to other countries where laboratories reported great strides last year. (Click here for more - a subscription may be required)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel